-+ 0.00%
-+ 0.00%
-+ 0.00%

NFL Biosciences Enrolls First Participant in Phase 2 Trial of NFL-102 for Smoking Cessation

PUBT·11/19/2026 06:58:55
Listen to the news
NFL Biosciences Enrolls First Participant in Phase 2 Trial of NFL-102 for Smoking Cessation
  • NFL Biosciences enrolled the first participant in its Phase 2 TONIC trial evaluating NFL-102 for smoking and nicotine cessation.
  • The placebo-controlled study plans to enroll 310 smokers in France, using an adaptive design to select the most effective dose.
  • Initial results from the 40-participant first stage are expected in April 2027; efficacy has not yet been established.
  • A second stage will enroll 270 additional participants to support dose selection and final evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NFL Biosciences SA published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.